Analyst consensus rating
Insight Molecular Diagnostics Analyst Rating: none
Direct answer
Insight Molecular Diagnostics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.25.
Forecast evidence checked November 14, 2026.
Get free Insight Molecular Diagnostics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.14
- Average price target
- $8.25
- High price target
- $12.00
- Low price target
- $4.00
- Low target gap
- +86.9%
- Target upside
- +285.5%
- High target gap
- +460.7%
- Target range width
- 373.8%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- November 14, 2026
- Valid through
- November 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Insight Molecular Diagnostics?
Insight Molecular Diagnostics has a verified none consensus. The same dataset has an average price target of $8.25.
How far are Insight Molecular Diagnostics's low and high targets from the recorded price?
The low target implies +86.9%, while the high target implies +460.7%.
How many analysts are included in Insight Molecular Diagnostics's consensus?
The verified consensus includes 4 analysts.
How is Insight Molecular Diagnostics's target upside or downside calculated?
The average target of $8.25 is divided by the recorded price of $2.14, then one is subtracted to produce +285.5%. This does not guarantee a future return.
When was Insight Molecular Diagnostics's analyst forecast verified?
The data was verified on 2026-11-14. The dataset is valid through 2026-11-21.